Clinical trials: Poor Performance Status
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern…
- Trial name
- NCT00085839
- Testing
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Where
- 19 sites in United States
- Volunteers
- 103 people
- Sponsor
- OSI Pharmaceuticals